Literature DB >> 30034955

Cyclophosphamide-induced Atrial Fibrillation With Rapid Ventricular Rate.

Komal Ejaz1, Muhammad A Raza2, Shahram Maroof3, Muhammad W Haider3.   

Abstract

Cyclophosphamide (CYA), also known as cytophosphane, is a medication used as a chemotherapeutic agent and immune suppressor.Its common adverse effects include nausea, vomitingdiarrhea, bone marrow suppression, hemorrhagic cystitis, alopecia, lethargy, and cardiotoxicity. Cyclophosphamide-related cardiac toxicity is not uncommon and causes potentially serious complications in patients. In this review, we present a case of a 65-years-old patient who developed atrial fibrillation with rapid ventricular rate (RVR) after receiving a single dose of CYA. In this case, the advanced age of the patient, pre-treatment with prednisone, and renal insufficiency most likely predisposed the patient to CYA-induced cardiac toxicity. A relevant literature review was also conducted to determine the pathogenesis, risk factors, and spectrum of CYA-induced cardiac toxicity.

Entities:  

Keywords:  cyclophosphamide induced atrial fibrillation; cyclophosphamide induced cardiotoxicity

Year:  2018        PMID: 30034955      PMCID: PMC6047839          DOI: 10.7759/cureus.2633

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  11 in total

1.  Fatal haemorrhagic myocarditis secondary to cyclophosphamide therapy.

Authors:  I W Birchall; Z Lalani; P Venner; J Hugh
Journal:  Br J Radiol       Date:  2000-10       Impact factor: 3.039

2.  Prognostic value and determinants of a hypointense infarct core in T2-weighted cardiac magnetic resonance in acute reperfused ST-elevation-myocardial infarction.

Authors:  Ingo Eitel; Konrad Kubusch; Oliver Strohm; Steffen Desch; Yoko Mikami; Suzanne de Waha; Matthias Gutberlet; Gerhard Schuler; Matthias G Friedrich; Holger Thiele
Journal:  Circ Cardiovasc Imaging       Date:  2011-04-25       Impact factor: 7.792

3.  Cardiac and pulmonary toxicity in patients undergoing high-dose chemotherapy for lymphoma and breast cancer: prognostic factors.

Authors:  B E Brockstein; C Smiley; J Al-Sadir; S F Williams
Journal:  Bone Marrow Transplant       Date:  2000-04       Impact factor: 5.483

4.  Effect of corticosteroids on the expression of cytochromes P450 and on cyclosporin A oxidase activity in primary cultures of human hepatocytes.

Authors:  L Pichard; I Fabre; M Daujat; J Domergue; H Joyeux; P Maurel
Journal:  Mol Pharmacol       Date:  1992-06       Impact factor: 4.436

Review 5.  Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis.

Authors:  M I Gharib; A K Burnett
Journal:  Eur J Heart Fail       Date:  2002-06       Impact factor: 15.534

6.  Cardiac toxicity following high-dose cyclophosphamide, cisplatin, and BCNU (STAMP-I) for breast cancer.

Authors:  Y Nieto; P J Cagnoni; S I Bearman; E J Shpall; S Matthes; R B Jones
Journal:  Biol Blood Marrow Transplant       Date:  2000       Impact factor: 5.742

7.  Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor.

Authors:  M A Goldberg; J H Antin; E C Guinan; J M Rappeport
Journal:  Blood       Date:  1986-11       Impact factor: 22.113

8.  Cardiac toxicity observed in association with high-dose cyclophosphamide-based chemotherapy for metastatic breast cancer.

Authors:  Amy Tiersten; Jennifer Wo; Caron Jacobson; Aaron Weitzman; Tamara Horwich; Charles Hesdorffer; David Savage; Andrea Troxel
Journal:  Breast       Date:  2004-08       Impact factor: 4.380

Review 9.  Cardiotoxicity of cytotoxic drugs.

Authors:  Kirsten J M Schimmel; Dick J Richel; Renée B A van den Brink; Henk-Jan Guchelaar
Journal:  Cancer Treat Rev       Date:  2004-04       Impact factor: 12.111

10.  Cyclophosphamide-Induced Cardiomyopathy: A Case Report, Review, and Recommendations for Management.

Authors:  Sumandeep Dhesi; Michael P Chu; Gregg Blevins; Ian Paterson; Loree Larratt; Gavin Y Oudit; Daniel H Kim
Journal:  J Investig Med High Impact Case Rep       Date:  2013-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.